JP2020523384A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523384A5 JP2020523384A5 JP2019569364A JP2019569364A JP2020523384A5 JP 2020523384 A5 JP2020523384 A5 JP 2020523384A5 JP 2019569364 A JP2019569364 A JP 2019569364A JP 2019569364 A JP2019569364 A JP 2019569364A JP 2020523384 A5 JP2020523384 A5 JP 2020523384A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- lymphoma
- seq
- adc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1709439.2A GB201709439D0 (en) | 2017-06-14 | 2017-06-14 | Dosage regime |
| GB1709439.2 | 2017-06-14 | ||
| GB1709441.8 | 2017-06-14 | ||
| GBGB1709441.8A GB201709441D0 (en) | 2017-06-14 | 2017-06-14 | Dosage regime |
| GB1710493.6 | 2017-06-30 | ||
| GBGB1710493.6A GB201710493D0 (en) | 2017-06-30 | 2017-06-30 | Dosage regime |
| GBGB1710496.9A GB201710496D0 (en) | 2017-06-30 | 2017-06-30 | Dosage regime |
| GB1710496.9 | 2017-06-30 | ||
| GB1720544.4 | 2017-12-08 | ||
| GBGB1720541.0A GB201720541D0 (en) | 2017-12-08 | 2017-12-08 | Dosage regime |
| GBGB1720544.4A GB201720544D0 (en) | 2017-12-08 | 2017-12-08 | Dosage regime |
| GB1720541.0 | 2017-12-08 | ||
| GBGB1803298.7A GB201803298D0 (en) | 2018-02-28 | 2018-02-28 | Dosage regime |
| GB1803298.7 | 2018-02-28 | ||
| PCT/EP2018/065862 WO2018229218A1 (en) | 2017-06-14 | 2018-06-14 | Dosage regimes for the administration of an anti-cd25 adc |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020523384A JP2020523384A (ja) | 2020-08-06 |
| JP2020523384A5 true JP2020523384A5 (enExample) | 2021-07-26 |
Family
ID=62636210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019569364A Pending JP2020523384A (ja) | 2017-06-14 | 2018-06-14 | 抗ｃｄ２５ ａｄｃを投与するための投与レジメ |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11426467B2 (enExample) |
| EP (1) | EP3638372A1 (enExample) |
| JP (1) | JP2020523384A (enExample) |
| KR (1) | KR20200028950A (enExample) |
| AU (1) | AU2018285455A1 (enExample) |
| BR (1) | BR112019026498A2 (enExample) |
| CA (1) | CA3064681A1 (enExample) |
| MX (1) | MX2019014923A (enExample) |
| WO (1) | WO2018229218A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3098103A1 (en) * | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
| GB201908128D0 (en) | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| JP2022536140A (ja) * | 2019-06-10 | 2022-08-12 | アーデーセー セラピューティクス ソシエテ アノニム | 併用療法 |
| GB201917254D0 (en) * | 2019-11-27 | 2020-01-08 | Adc Therapeutics Sa | Combination therapy |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| TW202513593A (zh) * | 2023-09-08 | 2025-04-01 | 大陸商信達生物製藥（蘇州）有限公司 | 半胱胺酸改造的抗體和免疫綴合物 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| AU2003295471B2 (en) | 2002-11-15 | 2011-08-25 | Genmab A/S | Human monoclonal antibodies against CD25 |
| NZ567140A (en) | 2005-10-07 | 2011-09-30 | Exelixis Inc | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
| ES2476602T3 (es) * | 2008-03-14 | 2014-07-15 | Bionumerik Pharmaceuticals, Inc. | Composiciones y métodos quimioprotectores |
| PT2906253T (pt) | 2012-10-12 | 2018-11-05 | Medimmune Ltd | Conjugados de anticorpo anti-psma de pirrolobenzodiazepina |
| EP2906297B1 (en) | 2012-10-12 | 2017-12-06 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
| PT2906252T (pt) | 2012-10-12 | 2017-09-19 | Medimmune Ltd | Conjugados de anticorpo anti-her2 de pirrolobenzodiazepina |
| DK2906298T3 (en) * | 2012-10-12 | 2018-12-17 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| WO2014057114A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| BR112015008238A2 (pt) | 2012-10-12 | 2017-11-28 | Adc Therapeutics Sarl | conjugados de pirrolbenzodiazepina-anticorpo anti-cd22 |
| WO2014057118A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
| KR101995620B1 (ko) | 2012-10-12 | 2019-07-03 | 에이디씨 테라퓨틱스 에스에이 | 피롤로벤조디아제핀-항체 컨주게이트 |
| WO2015052533A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| GB201406767D0 (en) | 2014-04-15 | 2014-05-28 | Cancer Rec Tech Ltd | Humanized anti-Tn-MUC1 antibodies anf their conjugates |
| CN107148285B (zh) * | 2014-11-25 | 2022-01-04 | Adc治疗股份有限公司 | 吡咯并苯并二氮杂䓬-抗体缀合物 |
| GB201506407D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506388D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Cancer Res Technology Ltd And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506393D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506394D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506399D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506405D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506389D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506409D0 (en) | 2015-04-15 | 2015-05-27 | Williams David G And Berkel Patricius H C Van And Howard Philip W | Humanized anti-axl antibodies and their conjugates |
| GB201507827D0 (en) | 2015-05-07 | 2015-06-17 | Adc Therapeutics Sarl | Diagnostic test |
| GB201513607D0 (en) * | 2015-07-31 | 2015-09-16 | Feingold Jay M | Pyrrolobenzodiazepine-antibody conjugates |
| JP7105188B2 (ja) * | 2015-08-25 | 2022-07-22 | ザ・ユー・エイ・ビー・リサーチ・フアンデーシヨン | 幹細胞移植方法 |
-
2018
- 2018-06-14 KR KR1020207001219A patent/KR20200028950A/ko not_active Ceased
- 2018-06-14 US US16/622,663 patent/US11426467B2/en active Active
- 2018-06-14 JP JP2019569364A patent/JP2020523384A/ja active Pending
- 2018-06-14 AU AU2018285455A patent/AU2018285455A1/en not_active Abandoned
- 2018-06-14 MX MX2019014923A patent/MX2019014923A/es unknown
- 2018-06-14 CA CA3064681A patent/CA3064681A1/en active Pending
- 2018-06-14 BR BR112019026498-1A patent/BR112019026498A2/pt not_active IP Right Cessation
- 2018-06-14 WO PCT/EP2018/065862 patent/WO2018229218A1/en not_active Ceased
- 2018-06-14 EP EP18732040.3A patent/EP3638372A1/en not_active Withdrawn
-
2022
- 2022-07-15 US US17/812,950 patent/US20230039868A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6628828B2 (ja) | Ｈｉｖを治療するためのトール様受容体の調節因子 | |
| JP2014533279A5 (enExample) | ||
| JP2019506403A5 (enExample) | ||
| JP2015534579A5 (enExample) | ||
| JP2015529225A5 (enExample) | ||
| JP2021502961A5 (enExample) | ||
| CN114286828A (zh) | 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法 | |
| JP2018506550A5 (enExample) | ||
| JP2015532292A5 (enExample) | ||
| JP2020524670A5 (enExample) | ||
| JP2014114288A5 (enExample) | ||
| JP2015534578A5 (enExample) | ||
| JP2019517485A5 (enExample) | ||
| JP2021523122A5 (enExample) | ||
| TW201919699A (zh) | 包含抗-cd38抗體及雷那度胺(lenalidomide)之組合物 | |
| JP6184952B2 (ja) | 抗ｃｄ１９抗体とナイトロゲンマスタードとの併用療法 | |
| JP6279065B2 (ja) | 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物 | |
| JP2020502219A5 (enExample) | ||
| RU2014117510A (ru) | Лечение ревматоидного артрита | |
| BR112013033916B1 (pt) | Uso de um anticorpo específico para cd19 | |
| JP2017160178A5 (enExample) | ||
| JP2018515493A5 (enExample) | ||
| JP2014525926A5 (enExample) | ||
| JP2019532970A5 (enExample) | ||
| JP2022512901A5 (enExample) |